Cambridge, MA based ARIAD Pharmaceuticals, Inc. (ARIA – Analyst Report) is a biopharmaceutical company focused on the discovery, development and commercialization of breakthrough treatments for cancer. ARIAD’s only approved product is Iclusig (ponatinib). Iclusig, a tyrosine kinase inhibitor (TKI), is approved both in the U.S. and EU for the treatment of adults suffering from T315I-positive chronic myeloid leukemia (chronic, accelerated or blast phase) or Philadelphia chromosome positive acute lymphoblastic leukemia or for whom no other TKI therapy is approved.
Search
New Posts
Mars to Buy Pringles Maker Kellanova for $36 Billion: A Big Deal in the Snack World
Volvo Cars to Deliver First EX90 SUVs This Month After Delay
Housing Market Filled With ‘Wait-and-See’ Home Buyers
AI Dataset Licensing Companies Form Trade Group
New Tom Hanks Film “Here” and the Unsettling ‘De-Aging’ Technology Keeping Stars Forever Young
Leave A Comment